Quantum BioPharma hires IR Agency for investor relations services

Quantum BioPharma Ltd. (NASDAQ: QNTM) announced it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC, beginning June 8, 2026.

The six-month agreement will cost the biopharmaceutical company $250,000. Under the terms, the agency will create company profiles, distribute information to the financial community, build a digital community, market news distribution, and conduct lead generation campaigns.

IR Agency LLC operates independently from Quantum BioPharma. The agency and its principals do not hold equity interests in the company's securities or rights to acquire such interests. Rafael Pereira will lead the investor relations services for the company.

Quantum BioPharma focuses on developing therapies for neurodegenerative and metabolic disorders and alcohol misuse disorders. The company's portfolio includes drug candidates in various development stages. Through its subsidiary Lucid Psycheceuticals Inc., Quantum is developing Lucid-MS, described as a compound designed to prevent and reverse myelin degradation associated with multiple sclerosis.

The company also created UNBUZZD and spun out its over-the-counter version to Unbuzzd Wellness Inc. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026. The arrangement includes royalty payments of 7% of sales until payments reach $250 million, after which royalties drop to 3% permanently.

The information is based on a company press release.

You May Also Be Interested In

• Magnolia Said In Lead To Acquire Wildfire For Over $4 Billion - Bloomberg
• AES stockholders approve $10.7 billion takeover by GIP and EQT
• Stardust Solar closes final tranche, raises $832,880 in total